title: [The Analysis of Efficacy of The Application of Interleukin-1 Inhibitor in the Complex Therapy of Secondary Osteoarthritis Taking Into Account the Dynamics of Clinical and Functional Indicators].
abstract: BACKGROUND
  Secondary osteoarthritis (OA) adversely affects the underlying disease and can enhance clinical manifestations of articular syndrome. Early detection of comorbid pathology and early treatment with the therapy of underlying condition is of primary importance to preserve adequate functional activity in patients. The Aim is to analyze the efficacy of the application of interleukin-1 inhibitor in the complex treatment of secondary OA in addition to rheumatoid arthritis (RA).
  
  
  METHODS
  248 patients with secondary OA and RA were divided in 4 groups: patients of group I (n = 62) took interleukin-1 inhibitor (50 mg x 2 times per day) in combination with laser therapy on the basis of methotrexate (10-20 mg per week), group II (n = 60) received interleukin-1 inhibitor in complex with methotrexate, in group III (n = 62)--laser therapy with methotrexate and in group 4--methotrexate. We estimated the treatment efficacy in 3 and 6 months according to the dynamics of pain on VAS, indexes HAQ and KOOS.
  
  
  RESULTS
  according to VAS group 1 showed statistical significant reduction in pain on movement in 3 and 6 months of 28.53 mm (43.6%) and 31.3 mm (48%) respectively, to values of 36.87 ± 1.56* and 33.11 ± 1.11* (p < 0.05). The results showed the statistically significant advantage of HAQ dynamics in groups I and II in comparison with groups III, IV (p = 0.03). The most prominent statistically significant (p = 0.02) results according to the dynamics of index KOOS were noted in groups of patients who took diacerein (I and II) 6 months after the complex treatment.
  
  
  CONCLUSIONS
  the inclusion of interleukin-1 inhibitor in the complex treatment of secondary OA in patients with RA contributes to clinical improvement according to VAS (p = 0.03), index KOOS that reflects functional condition of the knee and increases the quality of life by index HAQ (p = 0.03) after 6 months therapy.
authors: I A
authors: IA
authors: Starodubtseva
authors: L V
authors: LV
authors: Vasilieva
authors: A V
authors: AV
authors: Nikitin
mesh_terms: D000328:Adult; D000880:Anthraquinones / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000503:physiopathology / Q000523:psychology; D003131:Combined Modality Therapy / Q000379:methods; D016903:Drug Monitoring; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D053685:Laser Therapy / Q000379:methods; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D062072:Patient Acuity; D011788:Quality of Life; D020127:Recovery of Function / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000880:Anthraquinones; D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D007375:Interleukin-1; C025292:diacerein; D008727:Methotrexate